entire individual market to meet the Affordable Care Act's standard plans in 2014. California and 14 other states made this change-which all states were supposed to have completed by 2018, but with recent regulation by the Trump administration, many will never do. By not making this change, many healthier populations-because they previously underwent medical underwriting-have been excluded from the common risk pool.
Regardless of the number of plans in a marketplace, a key and often forgotten issue in how to keep premiums lower is marketing. By aggressively marketing plans, providers are likely to have a better risk mix, which fosters lower premiums. Two data points support the importance of marketing plans. First, based on recently released data from the Centers for Medicare and Medicaid Services in 2016, markets that were under the federal facilitated marketplace faced a net decline in enrollment of about 15% from the beginning of the year to the end of the year; this compares to a net decline of only 6% for those in statebased marketplaces. 3 This decline matters because declining enrollment is likely to mean that healthier people are leaving to be uninsured. Understanding the reason does require further study, but a key difference between federal and state-based marketplaces is that states have invested more in marketing that supports initial enrollment, enrollment throughout the year during special periods, and retention. The second data point relates to the core difference in marketing. Zhu and colleagues mention an increase in premiums for single-issuer regions of 25% compared with 7.2% the prior year. Too often, rate analysis looks at too short a window of time and at too few variables. Examining the combined weighted coverage of the second-lowest-cost Silver plan for 2016 and 2017 reveals that, in all of the 38 federal marketplace states, weighted coverage premium rates increased approximately 32.5% over 2 years. Compare this with an increase in the same period in California of 9.9% for the Silver plan with the second-lowest cost. The reason that premiums increased by more than 22.6% in federal marketplace states compared with that in California during 2016 and 2017 surely has multiple factors. However, limited plan competition is likely far less of a reason than the difference in marketing spending. California invests heavily in marketing-a mean annual 1.7% of the premium during 2016 and 2017.
Taken together with the recent data for enrollment year 2017 confirming that Covered California continues to have a strong, stable risk mix, these marketing investments seem to pay off in a big way to reduce premiums. 4, 5 Diagnosing the reason for premium increase variation is important and provides tools to policy makers. Part of this investigation should include looking at factors that contribute to poor performance and, just as important, to the factors that explain why California and many other health insurance markets have continued to be stable and competitive. 
LESS IS MORE

Evaluation of a Trainee-Led Project to Reduce Inappropriate Proton Pump Inhibitor Infusion in Patients With Upper Gastrointestinal Bleeding: Skip the Drips
Continuous infusion of proton pump inhibitors (PPIs) is recommended in patients with upper gastrointestinal bleeding (UGIB) for specific situations, such as before endoscopic identification of ulcers with high-risk features [1] [2] [3] [4] 
(Box).
Unfortunately, PPI infusions may be continued for 72 hours without indication. 2, 5 Reducing the overuse of these infusions is important because, in addition to increasing the length of stay and cost, PPI overuse is associated with various complications. 6 In July 2015, a fellow-and resident-led intervention was initiated with the goals of decreasing the inappropriate use of PPI infusions in patients with UGIB and promoting evidence-based care at lower costs for these patients.
Methods | This quality improvement study used the Culture, Oversight, Systems Change, Training framework. In July 2015, the electronic health record was changed to prompt physicians to select an appropriate indication for PPI infusion orders (systems change). Pharmacists tracked monthly usage of
Box. Indications for Continuous Intravenous Proton Pump Inhibitor (PPI) Infusion in Patients With Suspected or Established Upper Gastrointestinal Bleeding
Before Endoscopy
Recommended to reduce the number of patients with high-risk lesions at endoscopy PPI infusions (oversight). Education (training) was also provided in July 2015 for internal medicine residents, hospitalists, and emergency medicine faculty and residents. Trainees recruited faculty leaders from gastroenterology, general medicine, and emergency medicine departments to champion this initiative (culture). Institutional leaders at the University of Chicago sponsored this intervention via the Choosing Wisely challenge. This study was determined to be quality improvement, rather than human participant, research by the University of Chicago Office of Clinical Effectiveness and was therefore exempted from institutional review board approval. From July 2015 to April 2016, PPI infusion usage, indication, and endoscopic findings were prospectively collected. Data from patients admitted for UGIB in the preceding year (July 2014 to June 2015) served as historical controls.
We used a statistical process control chart method to examine the differences in inappropriate PPI infusion use between the preintervention (July 2014 to June 2015) and postintervention (July 2015 to April 2016) periods. We also used the 2-sample test of proportions (2-sided P value, with P < .05 considered statistically significant) to assess the rates of inappropriate PPI infusion use in a concurrent control group of surgical patients whose physicians did not receive the education but had access to the electronic health record changes. Time-driven, activity-based costing analysis was used to calculate total cost savings based on US Department of Labor wages for nursing and pharmacy with Stata software, version 14.0 (StataCorp LP).
Results | The inappropriate use of PPI infusion significantly decreased from a preintervention mean of 50% (95% CI, 45.1%-54.7%) to a postintervention mean of 15% (95% CI, 10.0%-18.5%), a 35% reduction (95% CI, −44.6% to −27.1%; P < .001) (Figure) . After the intervention, PPI infusions were significantly more likely to be discontinued after endoscopy (23 of 35 [65.7%]; 95% CI, 50.0%-81.4% vs 38 of 40 [92.5%]; 95% CI, 84.3%-100%; P = .004). The total cost of a single PPI infusion was calculated to be $378 per day, whereas the estimated cost of administering PPIs twice daily was $100.87, yielding a cost savings of $277 per patient per day assuming all patients required twice-daily PPI administration. Conservative estimates indicated a savings of at least $121 000 in pharmacy costs across 9 months. These changes were not observed for surgical services in which physicians had access to electronic health record changes but no education although a nonsignificant decrease in the percentage of inappropriate PPI infusions occurred 6 months after the intervention was launched (32 of 99 [32.3%]; 95% CI, 23.1%-41.5% vs 17 of 83 [20.5%]; 95% CI, 11.8%-29.2%; P = .08).
Discussion | This trainee-led intervention based on the Culture, Oversight, Systems Change, Training framework yielded a 35% decrease in inappropriate PPI infusions in patients with UGIB and a substantial cost savings in a 9-month period. Access to the systems change alone did not result in significant changes, highlighting the importance of including all aspects of the framework in the intervention.
Our quality improvement study was limited by a lack of both randomization and blinding. In addition, we did not determine the number of patients who were discharged with inappropriate PPI therapy and did not explore complications associated with inappropriate PPI usage.
This trainee-led, institution-supported, interdisciplinary intervention based on the Culture, Oversight, Systems Change, Training framework resulted in high-value, guideline-based care for inpatients with UGIB. Further research will be required to determine the durability of the intervention and unnecessary complications associated with PPI infusion overuse. 
Mean
Statistical process control chart showing rates of inappropriate PPI use before and after the intervention. The mean, upper control limit (+3 SDs), and lower control limit (−3 SDs) were calculated based on preintervention data.
Letters
Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth
The drug 17-alpha hydroxyprogesterone caproate is an injectable synthetic progestin. It has been proven effective in preventing or delaying preterm birth in singleton pregnancies for women with a history of spontaneous preterm birth. 1 Once widely available as an inexpensive compounded drug, it now has a branded version (Makena; AMAG Pharmaceuticals) that costs approximately 100 times more than the original. On February 4, 2011, KV Pharmaceutical Company (later renamed Lumara) received approval from the US Food and Drug Administration to manufacture and market Makena, which is composed of the same active ingredients as found in the original compounded formulation. The approval included an orphan drug designation and gave KV Pharmaceutical Company the exclusive rights to manufacture Makena, which potentially contributed to its high listed price. 2 For this study,
we used an insurance claims database to examine prescriptions for 17-alpha hydroxyprogesterone caproate among nearly 4000 commercially insured (not Medicaid) pregnant women.
Our aim was to understand the use, costs, and outcomes of the branded and compounded versions of the drug.
Methods | We searched a deidentified insurance claims database of individuals who had medical and pharmacy coverage through a large national private insurance provider from January 1, 2008, to December 31, 2015. This study was approved by the Harvard Medical School Institutional Review Board. Consent to use the data was included in the approval, and no patients were directly contacted.
To characterize trends in utilization of branded and compounded 17-alpha hydroxyprogesterone caproate, we used National Drug Code descriptors to identify women who had a pharmacy claim for either the branded or the compounded formulation. In addition, using a unique Current Procedural Terminology code, we identified women who received an injection of the compounded drug from a homecare agency. We used International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification (ICD-10-CM) codes to restrict the study to women whose outcome of delivery was a single liveborn or stillborn (ICD-9-CM V27.0 and V.27.1; ICD-10-CM Z37.0 and Z37.1). All analyses were performed on this cohort of women.
To characterize costs, we calculated the total allowed cost for each woman from the first injection of 17-alpha hydroxyprogesterone caproate to delivery. This cost reflected the final negotiated price before any discounts were applied.
To characterize outcomes associated with utilization of branded and compounded 17-alpha hydroxyprogesterone caproate, we compared rates of preterm birth using logistic regression that controlled for maternal age. Preterm deliveries were identified using ICD-9-CM codes 644.2, 644.20, and 644.21 as well as ICD-10-CM codes O42.011 to O42.919 and O60.10 to O60.10X9.
Results | From January 1, 2008, to December 31, 2015, a total of 535 women (540 pregnancies) received the branded drug and 3350 women (3481 pregnancies) received the compounded drug (Table) . Use of both formulations rose over time 
